stockrowViatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) EPS (diluted)
Viatris Inc.'s EPS (diluted) for fiscal 2025 was −$3.00, compared with −$0.53 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.53. Over the past ten years it has ranged from −$3.00 (fiscal 2025) to $1.71 (fiscal 2022) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 3 consecutive fiscal years. Viatris Inc. ranks 42nd of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.00 | — |
| FY2024 | −$0.53 | — |
| FY2023 | $0.05 | (97.08%) |
| FY2022 | $1.71 | — |
| FY2021 | −$1.05 | — |
| FY2020 | −$1.11 | — |
| FY2019 | $0.03 | (95.59%) |
| FY2018 | $0.68 | (47.69%) |
| FY2017 | $1.30 | 41.30% |
| FY2016 | $0.92 | (45.88%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.28 | — |
| Jun 2026 | −$0.10 | — |
| Mar 2026 | $0.15 | — |
| Dec 2025 | −$0.30 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $26.50 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $0.43 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement